Monday, September 3, 2012

EISAI RECEIVES APPROVAL FOR ANTICANCER AGENT HALAVEN® IN SOUTH KOREA

Eisai Co., Ltd. has received approval from the regulatory authorities in South Korea to market the anticancer agent Halaven® (eribulin mesylate) for the treatment of locally advanced or metastatic breast cancer patients who previously have been treated with at least two prior chemotherapies, including an anthracycline and a taxane. Halaven is the anticancer agent to be discovered and developed by Eisai in-house, and is the only single-agent chemotherapy to demonstrate a statistically significant overall survival (OS) benefit in Phase III studies (EMBRACE study) conducted in pretreated advanced and metastatic breast cancer patients. Including South Korea, Halaven is currently approved in 38 countries worldwide. South Korea is the third largest market in Asia after Japan and China, and constitutes the 12th largest pharmaceutical market in the world.